Login to Your Account



Clinic Roundup


Tuesday, March 19, 2013

• Merrimack Pharmaceuticals Inc., of Cambridge, Mass., enrolled its last patient in a Phase II, open-label, randomized trial of MM-121, a human monoclonal antibody, in combination with paclitaxel, compared to paclitaxel alone in advanced ovarian cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription